Incyte

FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
FDA Panel Splits on Lilly Arthritis Drug, Backs Lower of Two Doses
Xconomy
Eli Lilly
FDA
advisory panels
rheumatoid arthritis
baricitinib
Incyte
Flag link:
Big Week Ahead for Eli Lilly: Here's What to Look For
Big Week Ahead for Eli Lilly: Here's What to Look For
Motley Fool
Eli Lilly
earnings
FDA
Incyte
olumiant
rheumatoid arthritis
Flag link:
3 Biotech Stocks With Major Catalysts Incoming
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Incyte
TG Therapeutics
Cara Therapeutics
CR845
opioids
ublituximab
leukemia
olumiant
rheumatoid arthritis
Flag link:
[video]Why One Drug Flop Tanked Incyte's Stock
[video]Why One Drug Flop Tanked Incyte's Stock
Motley Fool
Incyte
epacadostat
Flag link:
Incyte's Horrible News Derails a Promising Class of Cancer Drugs
Incyte's Horrible News Derails a Promising Class of Cancer Drugs
Motley Fool
Incyte
Merck
epacadostat
IDO inhibitors
Roche
NewLink Genetics
Flag link:
How a Biotech Bummer Sent Nektar Therapeutics Stock South Today
How a Biotech Bummer Sent Nektar Therapeutics Stock South Today
Motley Fool
Nektar Therapeutics
Incyte
Merck
NKTR-214
Bristol-Myers Squibb
Flag link:
Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment
Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment
Marketwatch
Incyte
Merck
melanoma
epacadostat
Keytruda
clinical trials
metastatic melanoma
Flag link:
3 Biotechs That Could Get Big Boosts in April
3 Biotechs That Could Get Big Boosts in April
Motley Fool
biotech
GW Pharma
Epidiolex
Incyte
olumiant
baricitinib
Neurocrine Biosciences
Elagolix
Flag link:
Incyte study could bring lessons for cancer immunotherapy
Incyte study could bring lessons for cancer immunotherapy
Biopharma Dive
Incyte
cancer immunotherapy
metastatic melanoma
Merck
Keytruda
Flag link:
Concert rethinks R&D plans after loss in Incyte patent case
Concert rethinks R&D plans after loss in Incyte patent case
Fierce Biotech
Concert Pharmaceuticals
Incyte
patents
R&D
CTP-543
Flag link:
JPM18: Incyte and Syros to collaborate in cancer R&D
JPM18: Incyte and Syros to collaborate in cancer R&D
Biopharma Dive
Incyte
Syros Pharmaceuticals
cancer
R&D
JPMHC 2018
Flag link:
5 Biggest New Drugs of 2018
5 Biggest New Drugs of 2018
Motley Fool
Gilead Sciences
Bictegravir/F/TAF
Novo Nordisk
semaglutide
Ozempic
Incyte
epacadostat
AbbVie
Rova-T
Celgene
ozanimod
Flag link:
Why These 3 Biotech Stocks Could Outperform Their Peers In 2018
Why These 3 Biotech Stocks Could Outperform Their Peers In 2018
Investors Business Daily
biotech
Puma Biotechnology
Incyte
Clovis Oncology
Flag link:
3 Promising Cancer Immunotherapies to Watch in 2018
3 Promising Cancer Immunotherapies to Watch in 2018
Yahoo/Motley Fool
cancer
immuno-oncology
Incyte
epacadostat
Bristol-Myers Squibb
relatlimab
Nektar
NKTR-214
Flag link:
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
Flag link:
8 Takeout targets to watch in 2018
8 Takeout targets to watch in 2018
BioPharma Dive
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
Flag link:
Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte
Bristol-Myers offers a positive snapshot on early data for an IDO1 rival to Incyte
Endpoints
Bristol-Myers Squibb
IDO1
BMS-986205
Incyte
bladder cancer
cervical cancer
Flag link:
AstraZeneca plans new pivotal lung cancer trial with Incyte
AstraZeneca plans new pivotal lung cancer trial with Incyte
Yahoo/Reuters
AstraZeneca
Incyte
clinical trials
Imfinzi
epacadostat
lung cancer
Flag link:
Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics
Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics
Endpoints
Incyte
PD-1 inhibitors
Macrogenics
MGA012
Flag link:
That $1.25B Bristol-Myers IDO1 drug? Incyte claims a former staffer stole it
That $1.25B Bristol-Myers IDO1 drug? Incyte claims a former staffer stole it
Endpoints
Bristol-Myers Squibb
IDO1
Incyte
Flexus
Flag link:

Pages